Eli Lilly and (LLY) revenue breakdown
By product, Net product revenue is the largest at 94% of fiscal 2025 revenue, growing 22% a year over 5 years.
By region, United States is the largest at 67% of fiscal 2025 revenue, growing 23% a year over 6 years.
Revenue by product
Fiscal years, as Eli Lilly and reports them in its 10-K filings; fiscal 2025 total $65.2B.
| Products | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Share |
|---|---|---|---|---|---|---|---|
| Net product revenue | $22.7B | $26.0B | $25.5B | $28.8B | $40.7B | $61.0B | 94% |
| Collaboration and Other Revenue | — | — | $3.1B | $5.3B | $4.3B | $4.2B | 6% |
| Jardiance | $1.2B | — | — | — | — | — | — |
| Olumiant | — | $1.1B | — | — | — | — | — |
| Basaglar | — | $892M | — | — | — | — | — |
| Trajenta (BI) | $358M | $372M | — | — | — | — | — |
| Tyvyt® | $309M | — | — | — | — | — | — |
Revenue by region
Fiscal years, as Eli Lilly and reports them in its 10-K filings; fiscal 2025 total $65.2B.
| Regions | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Share |
|---|---|---|---|---|---|---|---|---|
| United States | $12.7B | $14.2B | $16.8B | $18.2B | $21.8B | $30.4B | $43.5B | 67% |
| Europe | $3.8B | $4.2B | $4.8B | $4.3B | $6.2B | $6.9B | $11.6B | 18% |
| Rest of world | $2.3B | $2.4B | $2.7B | $2.9B | $2.9B | $4.3B | $6.1B | 9% |
| JAPAN | $2.5B | $2.6B | $2.4B | $1.7B | $1.7B | $1.8B | $2.1B | 3% |
| China | $939M | $1.1B | $1.7B | $1.5B | $1.5B | $1.7B | $2.0B | 3% |
Every line, every quarterThe deep dive has fifteen-plus years of statements, quarterly results, charts and valuation models for LLY.
Open LLY in InvestinglyQuestions
Where does Eli Lilly and make its money?
In fiscal 2025, by product: Net product revenue $61.0B, Collaboration and Other Revenue $4.2B.
From Eli Lilly and's annual reports filed with the SEC (XBRL data), standardised by Investingly. Information only, not investment advice.